| Range: | 3.012-6.97 | Vol Avg: | 136896 | Last Div: | 0 | Changes: | 0.11 |
| Beta: | 1.22 | Cap: | 0.06B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu May 31 2018 | Empoloyees: | 31 | ||
| CUSIP: | 29415J106 | CIK: | 0001661053 | ISIN: | US29415J1060 | Country: | US |
| CEO: | Mr. Robert A. Berman | Website: | https://www.envveno.com | ||||
NVNO 3.40 Stock Price enVVeno Medical Corporation
enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow